RLAY Stock Overview
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Relay Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.95 |
| 52 Week High | US$13.32 |
| 52 Week Low | US$5.78 |
| Beta | 1.63 |
| 1 Month Change | -23.62% |
| 3 Month Change | -39.59% |
| 1 Year Change | -49.49% |
| 3 Year Change | -82.23% |
| 5 Year Change | n/a |
| Change since IPO | -83.02% |
Recent News & Updates
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%
Apr 17
Relay Therapeutics: Platform More Important Than Programs
Mar 13Recent updates
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%
Apr 17Relay Therapeutics: Platform More Important Than Programs
Mar 13Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag
Feb 13Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)
Jan 21We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth
Nov 14Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?
Jun 08Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Feb 22Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?
Oct 23Relay set to Equal Weight at Barclays; says fairly valued ahead of catalysts
Sep 30Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform
Sep 18Why did Relay Therapeutics stock drop today?
Sep 09Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)
Jan 02Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Reducing Their Forecasts For This Year
Aug 17Relay Therapeutics, Inc. (NASDAQ:RLAY) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 16Relay Therapeutics (NASDAQ:RLAY) Is In A Strong Position To Grow Its Business
Mar 26Read This Before Selling Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares
Feb 01
Relay Therapeutics inks deal for RLY-1971 with Genentech
Dec 14Relay Therapeutics (NASDAQ:RLAY) Is In A Strong Position To Grow Its Business
Dec 08Relay Therapeutics reports Q3 results
Nov 12Shareholder Returns
| RLAY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.7% | -2.5% | -3.2% |
| 1Y | -49.5% | -3.7% | 19.3% |
Return vs Industry: RLAY underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: RLAY underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| RLAY volatility | |
|---|---|
| RLAY Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RLAY's share price has been volatile over the past 3 months.
Volatility Over Time: RLAY's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 323 | Sanjiv Patel | www.relaytx.com |
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.
Relay Therapeutics, Inc. Fundamentals Summary
| RLAY fundamental statistics | |
|---|---|
| Market cap | US$780.52m |
| Earnings (TTM) | -US$341.97m |
| Revenue (TTM) | US$25.55m |
30.6x
P/S Ratio-2.3x
P/E RatioIs RLAY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RLAY income statement (TTM) | |
|---|---|
| Revenue | US$25.55m |
| Cost of Revenue | US$326.39m |
| Gross Profit | -US$300.84m |
| Other Expenses | US$41.13m |
| Earnings | -US$341.97m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.61 |
| Gross Margin | -1,177.64% |
| Net Profit Margin | -1,338.66% |
| Debt/Equity Ratio | 0% |
How did RLAY perform over the long term?
See historical performance and comparison